File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis

TitleLipoprotein lipase activator ameliorates the severity of dietary steatohepatitis
Authors
KeywordsSpecies Index: Mus
Issue Date2007
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/wps/find/journaldescription.cws_home/622790/description
Citation
Biochemical And Biophysical Research Communications, 2007, v. 356 n. 1, p. 53-59 How to Cite?
AbstractDietary model of steatohepatitis was established by feeding mice a methionine choline deficient (MCD) diet. Mice on MCD or control diet for 3 weeks were treated with or without NO-1886, a newly synthetic lipoprotein lipase (LPL) activator. In a separate experiment, NO-1886 was given after pre-treatment with 3 weeks of MCD diet. NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). In addition, NO-1886 dampened hepatic steatosis via accelerating fatty acid oxidation caused by enhanced expression of PPARα, cytochrome P450-10 (Cyp4a10), and Acyl-CoA oxidase (ACO). It failed to regulate genes of fatty acid uptake and synthesis pathways. In conclusion, NO-1886 ameliorated and induced regression of experimental steatohepatitis via increasing endogenous LPL activation resulting in suppression on pro-inflammatory factors and reduction of hepatic fatty acids. These findings indicate that NO-1886 is a potential therapeutic agent for steatohepatitis. © 2007 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/132852
ISSN
2014 Impact Factor: 2.297
2014 SCImago Journal Rankings: 1.006
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYu, Jen_HK
dc.contributor.authorChu, ESHen_HK
dc.contributor.authorHui, AYen_HK
dc.contributor.authorCheung, KFen_HK
dc.contributor.authorChan, HLYen_HK
dc.contributor.authorLeung, WKen_HK
dc.contributor.authorFarrell, GCen_HK
dc.contributor.authorSung, JJYen_HK
dc.date.accessioned2011-04-04T07:57:26Z-
dc.date.available2011-04-04T07:57:26Z-
dc.date.issued2007en_HK
dc.identifier.citationBiochemical And Biophysical Research Communications, 2007, v. 356 n. 1, p. 53-59en_HK
dc.identifier.issn0006-291Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/132852-
dc.description.abstractDietary model of steatohepatitis was established by feeding mice a methionine choline deficient (MCD) diet. Mice on MCD or control diet for 3 weeks were treated with or without NO-1886, a newly synthetic lipoprotein lipase (LPL) activator. In a separate experiment, NO-1886 was given after pre-treatment with 3 weeks of MCD diet. NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). In addition, NO-1886 dampened hepatic steatosis via accelerating fatty acid oxidation caused by enhanced expression of PPARα, cytochrome P450-10 (Cyp4a10), and Acyl-CoA oxidase (ACO). It failed to regulate genes of fatty acid uptake and synthesis pathways. In conclusion, NO-1886 ameliorated and induced regression of experimental steatohepatitis via increasing endogenous LPL activation resulting in suppression on pro-inflammatory factors and reduction of hepatic fatty acids. These findings indicate that NO-1886 is a potential therapeutic agent for steatohepatitis. © 2007 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/wps/find/journaldescription.cws_home/622790/descriptionen_HK
dc.relation.ispartofBiochemical and Biophysical Research Communicationsen_HK
dc.subjectSpecies Index: Musen_US
dc.subject.meshAnimalsen_HK
dc.subject.meshBenzamides - administration & dosage - pharmacologyen_HK
dc.subject.meshCholesterol - blooden_HK
dc.subject.meshCholine Deficiencyen_HK
dc.subject.meshCyclooxygenase 2 - genetics - metabolismen_HK
dc.subject.meshDiet - adverse effectsen_HK
dc.subject.meshEnzyme Activation - drug effectsen_HK
dc.subject.meshFatty Liver - blood - etiology - prevention & controlen_HK
dc.subject.meshGene Expression - drug effectsen_HK
dc.subject.meshHypolipidemic Agents - administration & dosage - pharmacologyen_HK
dc.subject.meshIntercellular Adhesion Molecule-1 - genetics - metabolismen_HK
dc.subject.meshInterleukin-6 - genetics - metabolismen_HK
dc.subject.meshLipogenesis - geneticsen_HK
dc.subject.meshLipoprotein Lipase - genetics - metabolismen_HK
dc.subject.meshLipoproteins, HDL - blooden_HK
dc.subject.meshLiver - drug effects - metabolism - pathologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMethionine - deficiencyen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred C57BLen_HK
dc.subject.meshOrganophosphorus Compounds - administration & dosage - pharmacologyen_HK
dc.subject.meshPPAR gamma - genetics - metabolismen_HK
dc.subject.meshRNA, Messenger - genetics - metabolismen_HK
dc.subject.meshThiobarbituric Acid Reactive Substances - metabolismen_HK
dc.subject.meshTumor Necrosis Factor-alpha - genetics - metabolismen_HK
dc.titleLipoprotein lipase activator ameliorates the severity of dietary steatohepatitisen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, WK:waikleung@hku.hken_HK
dc.identifier.authorityLeung, WK=rp01479en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.bbrc.2007.02.129en_HK
dc.identifier.pmid17350593en_HK
dc.identifier.scopuseid_2-s2.0-33947172627en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33947172627&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume356en_HK
dc.identifier.issue1en_HK
dc.identifier.spage53en_HK
dc.identifier.epage59en_HK
dc.identifier.eissn1090-2104-
dc.identifier.isiWOS:000245419300009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYu, J=35351306800en_HK
dc.identifier.scopusauthoridChu, ESH=8631130300en_HK
dc.identifier.scopusauthoridHui, AY=7102453670en_HK
dc.identifier.scopusauthoridCheung, KF=7402406701en_HK
dc.identifier.scopusauthoridChan, HLY=16038785900en_HK
dc.identifier.scopusauthoridLeung, WK=7201504523en_HK
dc.identifier.scopusauthoridFarrell, GC=7102979833en_HK
dc.identifier.scopusauthoridSung, JJY=35405352400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats